Campion Simon D
Campion Simon D's purchase track record
Campion Simon D has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/12/2024 | XRAY | $200K | +3.7% | -4.8% | -1.6% |
| 11/20/2023 | XRAY | $297K | +13.2% | -5.2% | +16.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
BDX Revello Stent Trial Success, Revenue Up 5.4%, Earnings Down 34%. The company announced that its Revello stent achieved strong results in the AGILITY trial for peripheral artery disease patients. Revenue rose 5.4% year‑over‑year, but net earnings fell 34.3%, reflecting higher costs or lower margins. The dividend yield sits at 1.59% and analysts see a target of $194, while the stock trades near the top of its 52‑week range.
Transaction History
| XRAY | ▼ Sell | Tax Withholding | 32,566 | $523K | 7/28/2025 | View on chart |
| XRAY | ▲ Buy | Grant | 1,261 | $0 | 7/11/2025 | View on chart |
| XRAY | ▲ Buy | Grant | 1,331 | $0 | 4/11/2025 | View on chart |
| XRAY | ▼ Sell | Tax Withholding | 4,849 | $76K | 3/4/2025 | View on chart |
| XRAY | ▼ Sell | Tax Withholding | 3,778 | $60K | 3/3/2025 | View on chart |
| XRAY | ▲ Buy | Grant | 1,289 | $0 | 1/10/2025 | View on chart |
| XRAY | ▲ Buy | Open Market | 11,306 | $200K | 11/12/2024 | View on chart |
| XRAY | ▲ Buy | Grant | 897 | $0 | 10/11/2024 | View on chart |
| XRAY | ▼ Sell | Tax Withholding | 33,729 | $856K | 9/12/2024 | View on chart |
| XRAY | ▲ Buy | Grant | 1,458 | $0 | 7/12/2024 | View on chart |
| XRAY | ▲ Buy | Grant | 1,089 | $0 | 4/12/2024 | View on chart |
| XRAY | ▲ Buy | Grant | 48,978 | $0 | 3/4/2024 | View on chart |
| XRAY | ▼ Sell | Tax Withholding | 3,651 | $121K | 3/1/2024 | View on chart |
| XRAY | ▲ Buy | Grant | 742 | $0 | 1/12/2024 | View on chart |
| XRAY | ▲ Buy | Open Market | 10,000 | $297K | 11/20/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 770 | $0 | 10/13/2023 | View on chart |
| XRAY | ▼ Sell | Tax Withholding | 30,208 | $1.1M | 9/12/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 917 | $0 | 7/14/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 931 | $0 | 4/14/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 37,106 | $0 | 3/3/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 877 | $0 | 1/13/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 223,357 | $0 | 11/15/2022 | View on chart |
| BDX | ▼ Sell | Gift | 50 | $0 | 2/11/2022 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 190 | $0 | 1/27/2022 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 650 | $0 | 11/26/2021 | View on chart |
| BDX | ▲ Buy | Grant | 1,748 | $0 | 11/26/2021 | View on chart |
| BDX | ▲ Buy | Grant | 1,027 | $0 | 11/26/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
XRAY: Earnings, Target Cut, Expansion, Medicare Coverage
XRAY reported its Q2 earnings, prompting analysts to review the company’s outlook. Piper Sandler lowered its target to $12, citing the reset strategy after a new Midwest dental partnership. Meanwhile, the Wellspect unit announced Medicare reimbursement for its Surity urinary portfolio, expanding the company’s product reach. These developments add new layers to XRAY’s growth narrative.
XRAY: Earnings, Target Cut, Expansion, Medicare Coverage. XRAY reported its Q2 earnings, prompting analysts to review the company’s outlook. Piper Sandler lowered its target to $12, citing the reset strategy after a new Midwest dental partnership. Meanwhile, the Wellspect unit announced Medicare reimbursement for its Surity urinary portfolio, expanding the company’s product reach. These developments add new layers to XRAY’s growth narrative.